Real-world outcomes from small-aperture lens implantation

Session Details

Session Title: Presented Poster Session: Enlarged Depth of Focus vs Multifocal IOLs

Venue: Poster Village: Pod 1

First Author: : E.Papamichael UK

Co Author(s): :    J. Fajardo-Sanchez   V. Rowe   G. Pramanik   B. Sewak   R. Jayaswal   R. Angunawela        

Abstract Details

Purpose:

To evaluate the clinical acceptability of implantation of the small aperture IC8 (Acufocus Inc, Irvine, USA) intraocular lens (IOL) in one eye and the implantation of monofocal IOL (aspheric or toric) in the fellow eye in patients undergoing bilateral cataract surgery or clear lens extraction retrospectively in real-world practices.

Setting:

Two large United Kingdom NHS and private practices – Moorfields Eye Hospital NHS Foundation Trust and Portsmouth Hospitals NHS Trust.

Methods:

A retrospective review of medical records of patients who underwent either cataract surgery or clear lens extraction with implantation of the IC8 IOL monocularly. Patients with co-pathology which could have affected the final visual outcome were excluded from the case review. Data on patient demographics, indication for IC8 implantation and corneal topography were collected. Pre and post-surgery monocular and binocular unaided and best-corrected distance (UDVA, BCDVA), and near (UNVA, BCNVA) visual acuities were collected as well as pre-operative and post-operative manifest refraction at 1, 3 and 6 months.

Results:

Here we report preliminary results of 10 patients included in the study. The commonest indication for implantation of the IC8 IOL in our cohort was hypermetropia with presbyopia (n=4, 40%) and cataract the second commonest indication (n=3, 10%) (LASIK n=2, 20%, and radial keratotomies (RKs) n=1, 10%). At the 6 months visit the spherical equivalent (SE) manifest refraction had changed from 0.53+/-1.01D pre-operatively to -0.75+/-0.16D post-operatively, as predicted based on the target refraction. Monocular UDVA and UNVA changed from 0.34+/-0.24 LogMAR and N13+/-4 pre-operatively to 0.06+/-0.07LogMAR (p<0.05) and N5+/-0.7 (p<0.0001) respectively post-operatively. There were no reported adverse effects.

Conclusions:

The evidence presented above supports the use of the IC8 IOL in patients that have presbyopia as well as previous refractive surgery and corneas with higher order aberrations. The IC8 IOL has shown good visual performance for the indications it was used for.

Financial Disclosure:

None